Latanoprost Elvim

Latanoprost, the active ingredient in Latanoprost Elvim, is a prostaglandin F2α analog presented as an ophthalmic solution for ocular use. It lowers intra‑ocular pressure and is employed in the management of glaucoma and ocular hypertension in adult patients. GNH USA supplies Latanoprost Elvim as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Latanoprost is used in ophthalmology to manage conditions that require reduction of intra‑ocular pressure. - Primary open‑angle glaucoma: reduces intra‑ocular pressure to slow disease progression. - Ocular hypertension: lowers eye pressure to prevent development of glaucoma.

Latanoprost may cause ocular and systemic reactions.

Common Side Effects: - Eye redness: mild conjunctival hyperemia. - Eye irritation or burning sensation upon instillation. - Blurred vision: transient visual disturbance. - Increased eyelash growth: longer, thicker lashes. - Darkening of iris: gradual pigmentation change. - Periocular skin darkening: mild hyperpigmentation.

Serious or Rare Side Effects: - Severe eye inflammation (uveitis or iritis). - Allergic reaction: swelling, itching, or rash around the eye. - Vision loss: sudden decrease in visual acuity. - Corneal ulcer or keratitis. - Persistent ocular pain or photophobia.

Patients should be advised of safety considerations before initiating therapy. - Monitor intra‑ocular pressure: regular IOP measurements are essential. - Assess for ocular infection: avoid use if active eye infection is present. - Avoid contact lenses: discontinue lens wear during treatment. - Inform ophthalmologist of any planned ocular surgery. - Store at room temperature: keep in original container, protect from light and moisture.

Latanoprost may interact with other ocular or systemic agents.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory eye drops: may diminish Latanoprost efficacy. - Combination with other prostaglandin analogs: risk of excessive IOP lowering. - Systemic prostaglandin synthesis inhibitors: potential antagonism.

Moderate Interactions (Monitor Closely): - Beta‑blocker eye drops: additive IOP‑lowering effect, monitor pressure. - Carbonic anhydrase inhibitor eye drops: increased risk of ocular side effects. - Corticosteroid eye drops: may counteract pressure‑lowering action.